MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$7,666K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accrued expenses
Change in fair value of converti...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Accounts receivable
Prepaid expenses
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-23,417
-25,073
-21,664
-16,238.45
Accretion of interest for royalty obligations
963
1,077
1,081
1,316
Change in fair value of convertible notes
-3,705
-9,632
-14,984
-
Depreciation of property and equipment
278
469
340
389
Amortization of intangible assets
1,043
1,031
877
679
Impairment of intangible assets
-
-
285
-
Amortization of debt discount
237
195
0
0.109
Lease amortization expense
-
-
-
74
Lease amortization expense
68
70
-169
243
Stock-based compensation
2,760
1,908
1,799
2,762.683
Inventory write-off
925
-
263
792
Gain on default judgment
-
-
0
-
Accounts receivable
2,782
2,842
870
7,940
Inventory
-1,218
-156
-393
-1,385
Prepaid expenses
385
-498
-531
1,463.959
Operating lease right-of-use assets
-105
-104
-345
-
Accounts payable
-338
3,161
-2,675
4,031
Accrued expenses
8,306
-1,908
3,474
2,689
Contingent consideration
0
-1,200
2,200
-
Operating lease liabilities
-167
-163
-93
-189
Deferred revenue
-183
-241
-883
294
Deferred income tax
-
-
7,852
-465
Other assets and liabilities
-
-
62
-97
Net cash used in operating activities
-7,664
-13,126
-6,252
-15,258.729
Purchases of property and equipment
2
194
99
-
Assets acquisition-Xepi Acquisition
-
-
6,080
-
Assets acquisition-XEGLYZEAsset Purchase Agreement
-
-
1,818
-
Acquisition of lnhc, inc
-
-
5,522
-2,761
Net cash used in investing activities
-2
-194
-7,997
2,761
Proceeds from pipe, net
-
-
0
27,384
Proceeds from stock option exercises
-
-
121
85
Proceeds from convertible note
-
-
17,898
-
Proceeds from venture loan and security agreement, net
0
29,337
-
-
Proceeds from loan payable, net of debt discount
0
0
0
68
Payment of loan payable, net of debt discount
-
-
845
-
Common stock issued for cash
-
-
0
-
Rescission of common stock
-
-
0
-
Repurchase of common stock under stock repurchase plan
-
-
0
-
Payment of loan payable, net of debt discount
-
-
-
-845
Shares issued for cash under equity line of credit
-
-
0
-
Payment of venture loan and security agreement issuance costs
0
1,814
-
-
Net cash provided by financing activities
0
27,523
18,019
26,692
Net increase (decrease) in cash and cash equivalents and restricted cash
-7,666
14,203
3,770
14,194.271
Cash, cash equivalents and restricted cash as of beginning of period
32,226
18,023
513
-
Cash, cash equivalents and restricted cash as of end of period
24,560
32,226
-
-
Cash and cash equivalents
24,192
31,976
-
-
Cash and cash equivalents at beginning of period
-
-
-
513
Restricted cash
368
250
-
-
Cash and cash equivalents at end of period
-
-
-
14,253
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
24,560
32,226
18,023
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$7,666K
(-1587.54%↓ Y/Y)
Accrued expenses
$8,306K
Change in fair value of
convertible notes
-$3,705K
Stock-based compensation
$2,760K
(206.90%↑ Y/Y)
Inventory
-$1,218K
Amortization of intangible
assets
$1,043K
Accretion of interest for
royalty obligations
$963K
Inventory write-off
$925K
Depreciation of property and
equipment
$278K
Amortization of debt discount
$237K
(-8.46%↓ Y/Y)
Operating lease
right-of-use assets
-$105K
Lease amortization
expense
$68K
Net cash used in
operating activities
-$7,664K
(-610.11%↓ Y/Y)
Net cash used in
investing activities
-$2K
Canceled cashflow
$19,608K
Net loss
-$23,417K
(-332.32%↓ Y/Y)
Purchases of property and
equipment
$2K
Accounts receivable
$2,782K
Prepaid expenses
$385K
(826.98%↑ Y/Y)
Accounts payable
-$338K
Deferred revenue
-$183K
Operating lease
liabilities
-$167K
Buy us a coffee
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)